Amphastar Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Amphastar Pharmaceuticals, Inc. (AMPH)
Last amphastar pharmaceuticals, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amphastar.com/investor-relations
Company Research
Source: Yahoo! Finance
performance— $185.4 million , up 12%—was offset by steep declines in legacy products (notably glucagon down 45%); Q4 net income fell to $24.4 million ($0.51/share) from $38.0 million a year earlier. The FDA approved Ipratropium Bromide HFA (AMP-007) For 2026 Amphastar expects consolidated revenue growth in the mid-to-high single-digit range but warns of lower gross margins due to pricing pressure on high-margin legacy products and a higher mix of lower-margin API sales, while ramping manufacturing capacity and financing expansion with operating cash flow. Interested in Amphastar Pharmaceuticals, Inc.? Here are five stocks we like better. Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts Amphastar Pharmaceuticals (NASDAQ:AMPH) executives on the company's fourth-quarter earnings call highlighted new FDA approvals, continued growth for BAQSIMI, and expectations for mid-to-high single-digit revenue growth in 2026, while acknowledging ongoing competitive and pricing press
Show less
Read more
Impact Snapshot
Event Time:
AMPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMPH alerts
High impacting Amphastar Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMPH
News
- Why Amphastar Pharmaceuticals (AMPH) Shares Are Plunging Today [Yahoo! Finance]Yahoo! Finance
- Amphastar Pharmaceuticals (AMPH) had its price target lowered by Wells Fargo & Company from $34.00 to $30.00. They now have an "overweight" rating on the stock.MarketBeat
- Amphastar Pharmaceuticals (AMPH) had its price target lowered by Needham & Company LLC from $34.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 CY2025 Revenue Estimates, Stock Drops 11.7% [Yahoo! Finance]Yahoo! Finance
- Amphastar Pharmaceuticals (AMPH) Reports Earnings Tomorrow: What To Expect [Yahoo! Finance]Yahoo! Finance
AMPH
Earnings
- 2/26/26 - Miss
AMPH
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- 1/12/26 - Form 8-K
- AMPH's page on the SEC website